Drug Profile
STP 909
Alternative Names: STP-909Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Sirnaomics
- Developer Sirnaomics; The Pennsylvania State University
- Class Antineoplastics; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cervical cancer; Human papillomavirus infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Cervical-cancer in USA (IV)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Cervical-cancer in USA (Topical)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in USA (IV)